Literature DB >> 7019707

Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin.

G R Freidenberg, N White, S Cataland, T M O'Dorisio, J F Sotos, J V Santiago.   

Abstract

Patients with diabetes that is insensitive to subcutaneous insulin but sensitive to intravenous insulin have recently been described. We have studied this phenomenon is five female diabetics (14 to 31 years of age) who required excessive amounts of insulin (2.5 to 30.0 units per kilogram of body weight per day) to avoid recurrent ketoacidosis. Known causes of insulin resistance were excluded. All patients had normal responses to conventional doses of intravenous insulin (0.35 to 0.9 unit per kilogram per day). Four patients required continuous intravenous infusion of insulin for one to six months. When a mixture of aprotinin (a protease inhibitor) and regular porcine insulin was given subcutaneously, conventional doses (0.7 to 1.4 units per kilogram per day) produced euglycemia; plasma levels of free insulin rose, and ketonuria disappeared. Four patients had episodes of spontaneous, severe hypoglycemia before and during aprotinin therapy, necessitating continuous infusion of glucose for two to 14 days. Although no insulin was administered, hyperinsulinemia (50 to 2000 muU of free insulin per milliliter [359 to 14,350 pmol per liter]) was present. These findings suggest excessive degradation or sequestration of insulin at the site of injection.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7019707     DOI: 10.1056/NEJM198108133050702

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  15 in total

1.  Inhibition of insulin degradation by hepatoma cells after microinjection of monoclonal antibodies to a specific cytosolic protease.

Authors:  K Shii; R A Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

2.  Subcutaneous degradation of insulin.

Authors:  R W Stevenson
Journal:  Diabetologia       Date:  1982-03       Impact factor: 10.122

3.  Brittle diabetes--present concepts.

Authors:  G V Gill; S Walford; K G Alberti
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

4.  Low subcutaneous degradation and slow absorption of insulin in insulin-dependent diabetic patients during continuous subcutaneous insulin infusion at basal rate.

Authors:  D J Chisholm; E W Kraegen; M J Hewett; S Furler
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

5.  Influence of aprotinin on insulin absorption and subcutaneous blood flow in type 1 (insulin-dependent) diabetes.

Authors:  B Linde; R Gunnarsson
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

6.  Unrecognised nocturnal hypoglycaemia masquerading as senile dementia.

Authors:  R Ramasamy
Journal:  Postgrad Med J       Date:  1983-09       Impact factor: 2.401

7.  Brittle diabetes: long-term control with a portable, continuous, intravenous insulin infusion system.

Authors:  J Bayliss
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-07

8.  Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors.

Authors:  M Takeyama; T Ishida; N Kokubu; F Komada; S Iwakawa; K Okumura; R Hori
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

9.  Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients.

Authors:  G Williams; J C Pickup; S Bowcock; E Cooke; H Keen
Journal:  Diabetologia       Date:  1983-02       Impact factor: 10.122

10.  Implantable infusion pump management of insulin resistant diabetes mellitus.

Authors:  H Buchwald; E P Chute; F J Goldenberg; C R Hitchcock; B J Hoogwerf; J J Barbosa; W M Rupp; T D Rohde
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.